

GLAX

B01

1993-272545/34

=RU 2120285-C1

Aerosol formulations contg. beclomethasone di:propionate mono:hydrate - have specified water content for prolonged stability

GLAXO GROUP LTD 1992.02.06 1992GB-002519

P34 (1998.10.20) *WO 9315741-A1 A61K 31/56, 9/12, A61L 9/04

1993.02.02 1994RU-040361

Compsn. comprises (by wt): a) beclomethasone dipropionate monohydrate (pref. 0.005-10%) of particle size substantially less than 20 microns alone or in combination with salbutamol or salmeterol xinafoate; (b) at least 0.015% pref. 0.026-0.08% of the formulation of water in addition to the water of crystallisation assoc. with said monohydrate and c) a fluorocarbon or hydrogen-contg. chlorofluorocarbon propellant (pref. 1,1,1,2,3,3,3-heptafluoro -n-propane or 1,1,1,2-tetrafluoroethane).

USE/ADVANTAGE - The formulations are stable and the particle size does not increase on storage due to solvates formulating so that the medicament particles do not become too large to penetrate the lungs. Daily doses of beclomethasone dipropionate are in the range (100-2000mcg given by filled canisters and metered dose inhalers, 1-4 puffs, 1-8 times per day
